Skip to main content English



Report Summary:

Call/Topic: FP7-HEALTH-2009-single stage: Living autologous heart valves for minimally invasive implantable procedures. Large scale integrating project.
Project duration: 11/2009 – 10/2014
Total costs: €9.8 mio
Contribution MUW: € 215 480
The Medical University of Vienna acted as a project partner led by Prof. Dr. Mariann Gyöngyösi, Clinical Department of Internal Medicine II, Division of Cardiology.
Project coordinator was Prof. Dr. Dr. Simon P. Hoerstrup, Regenerative Medicine and Organoid Technology Research Program (ReMedi), University of Zurich
Consortium: 8 partners

Living autologous heart valves for minimal invasive implantations (LifeValve)

LifeValve brought together a unique consortium of academic and industrial partners from Switzerland (Leading House), Germany, The Netherlands, Austria and Hungary. The principal objective of the LifeValve project was to develop a new therapeutic strategy to treat heart valve disease patients more efficiently.
The scientific and technological approach of the LifeValve project was to develop a clinically relevant tissue engineered living heart valve, with the capacity of regeneration and growth which can be implanted by minimally invasive catheter technology. A highly interdisciplinary approach combined basic sciences, medical research, engineering and clinical practice. The compact consortium was well interconnected and comprised all the necessary expertise and skills to realize the precisely planned work in a timeline of five years.


Arbeitsgruppe Univ. Prof. Univ.-Doz. Dr. Mariann Pavone-Gyöngyösi